Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells

Redox Biol. 2022 Jul:53:102324. doi: 10.1016/j.redox.2022.102324. Epub 2022 May 4.

Abstract

Myoferlin, an emerging oncoprotein, has been associated with a low survival in several cancer types including pancreas ductal adenocarcinoma where it controls mitochondria structure and respiratory functions. Owing to the high susceptibility of KRAS-mutated cancer cells to iron-dependent cell death, ferroptosis, and to the high iron content in mitochondria, we investigated the relation existing between mitochondrial integrity and iron-dependent cell death. We discovered that myoferlin targeting with WJ460 pharmacological compound triggered mitophagy and ROS accumulation culminating with lipid peroxidation and apoptosis-independent cell death. WJ460 caused a reduction of the abundance of ferroptosis core regulators xc- cystine/glutamate transporter and GPX-4. Mitophagy inhibitor Mdivi1 and iron chelators inhibited the myoferlin-related ROS production and restored cell growth. Additionally, we reported a synergic effect between ferroptosis inducers, erastin and RSL3, and WJ460.

Keywords: Ferroptosis; Mitochondria; Mitophagy; Myoferlin; Pancreas cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ferroptosis*
  • Humans
  • Iron / metabolism
  • Lipid Peroxidation
  • Mitophagy
  • Pancreas
  • Pancreatic Neoplasms* / genetics
  • Pancreatic Neoplasms* / metabolism
  • Reactive Oxygen Species / metabolism

Substances

  • Reactive Oxygen Species
  • Iron